Found 161 articles for: "ustekinumab"
Onset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read MoreTreatment of Scalp Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 833 | Copyright © August 2022
Scalp involvement is seen in a majority of individuals with psoriasis, a chronic autoimmune skin disease with variable phenotypes. Occasionally, isolated scalp involvement is observed; and this causes...
Read MoreSingle-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 864 | Copyright © August 2022
The efficacy of guselkumab has been demonstrated in randomized controlled trials, but real-life data are still missing. This study presents a single-center real-life experience in treating moderate-to...
Read MoreNail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
August 2022 | Volume 21 | Issue 8 | Editorials | 914 | Copyright © August 2022
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis...
Read MoreLong-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
April 2022 | Volume 21 | Issue 4 | Original Article | 399 | Copyright © April 2022
Background: There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-...
Read MoreLong-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics
April 2022 | Volume 21 | Issue 4 | Original Article | 364 | Copyright © April 2022
Background: Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain. Biologic therapies can vary in their effectiveness and adverse events,...
Read MoreA Case of Late-Onset Alopecia Areata
April 2022 | Volume 21 | Issue 4 | Case Reports | 420 | Copyright © April 2022
Alopecia areata (AA) is a condition characterized by nonscarring hair loss. Cases of alopecia areata are most commonly seen in patients under age 30 and are frequently idiopathic. In this report, we d...
Read MoreSuccessful Treatment of Cheilitis Granulomatosa With Certolizumab and Ustekinumab
March 2022 | Volume 21 | Issue 3 | Case Reports | 317 | Copyright © March 2022
Cheilitis granulomatosa (CG) is a subtype of orofacial granulomatosis that results in facial and oral swelling in the absence of non-caseating granulomatous systemic diseases such as Crohn’s and...
Read MoreUstekinumab in the Management of Hidradenitis Suppurativa: A Retrospective Study
March 2022 | Volume 21 | Issue 3 | Editorials | 319 | Copyright © March 2022
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by the formation of recurrent abscesses in apocrine-bearing areas. In advanced stages, chronic inflammation leads to...
Read MoreBimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 162 | Copyright © February 2022
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.
Objectives: To assess patients' abil...
Read MoreEarly Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
February 2022 | Volume 21 | Issue 2 | Original Article | 122 | Copyright © February 2022
Background: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.
O...
Read MoreTreatment of Nail Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 146 | Copyright © February 2022
Nail psoriasis has a considerable negative impact on the quality of life by limiting the patient’s household chores, professional activities and social interactions. Treatment for nail psoriasis...
Read MoreAn Overview of Biologics for Psoriasis
November 2021 | Volume 20 | Issue 11 | Features | 1246 | Copyright © November 2021
The use of biologics has revolutionized the treatment of psoriasis but choosing the right agent could be challenging. Currently, there are multiple biologic options, each with advantages and disadvant...
Read MoreSuccessful Treatment of Palmoplantar Pustulosis With Apremilast
November 2021 | Volume 20 | Issue 11 | Editorials | 1255 | Copyright © November 2021
Palmoplantar pustulosis (PPP) is a chronic, debilitating autoimmune skin disease characterized by the presence of recurrent neutrophilic pustules on acral surfaces. Although similarities exist, PPP is...
Read MoreBiological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
October 2021 | Volume 20 | Issue 10 | Original Article | 1063 | Copyright © October 2021
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We re...
Read MoreCharacteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database
October 2021 | Volume 20 | Issue 10 | Features | 1127 | Copyright © October 2021
Guselkumab is approved by the Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis. However, characteristics of patients initiating guselkumab in a real-world setting ...
Read MoreSustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
August 2021 | Volume 20 | Issue 8 | Original Article | 880 | Copyright © August 2021
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoria...
Read MoreSerious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
August 2021 | Volume 20 | Issue 8 | Original Article | 855 | Copyright © August 2021
Background: Anti-interleukin (IL)-17 biologic agents used to treat psoriasis are associated with onset/exacerbation of inflammatory bowel disease (IBD). Objectives: To determine the incidence of IBD o...
Read MoreAntihistamines in Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 844 | Copyright © August 2021
Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common a...
Read MoreReview of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 837 | Copyright © August 2021
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA)...
Read More